NICE OKs arthritis therapies, not pemetrexed for NSCLC

  • PDF / 123,511 Bytes
  • 1 Pages / 623.591 x 841.847 pts Page_size
  • 35 Downloads / 170 Views

DOWNLOAD

REPORT

10/0536-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

PharmacoEconomics & Outcomes News 8 Sep 2007 No. 536

1

Data Loading...

Recommend Documents
NICE recommends osimertinib for advanced EGFR-positive NSCLC

159 54 163KB

Cisplatin/pemetrexed

142 17 166KB

Carboplatin/pemetrexed

127 109 166KB

NICE recommends liraglutide & venetoclax + obinutuzumab, but not nivolumab

148 79 168KB

Nice Numbers

192 57 12MB

Carboplatin/pembrolizumab/pemetrexed

133 99 167KB

ICER favours vinorelbine + cisplatin for NSCLC

180 102 120KB

Erhaltungstherapie mit Pemetrexed

156 102 431KB

Carboplatin/pembrolizumab/pemetrexed

133 54 167KB

Carboplatin/loratadine/pemetrexed

121 49 166KB

Correction to: Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortal

144 107 236KB

Have a nice day!

144 88 2MB